ReviewNaunyn-Schmiedeberg's archives of pharmacology2025
Pinosylvin as a promising natural anticancer agent: mechanisms of action and future directions in cancer therapy.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluation of anti-cancer and Immunomodulatory effects of Globe Thistle (Echinops Shakrokii S.A. Ahmad) extracts: an in vitro and in vivo study.Scientific reports · 2025Article
- Ethnopharmacology ofFrontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a major global health challenge, with rising incidence necessitating alternative therapies. Pinosylvin, a natural phenolic compound in pine species, has demonstrated notable anticancer properties, making it a promising candidate for cancer treatment. This review synthesizes findings from extensive literature searches across databases, including PubMed and Scopus, to explore pinosylvin's efficacy against cancers like nasopharyngeal, prostate, colorectal, fibrosarcoma, and oral cancers. In vitro and in vivo studies indicate that pinosylvin disrupts cancer cell processes, such as migration and invasion, by targeting molecular pathways including MAPK, ERK, and PI3K. Its anti-inflammatory, antioxidant, and antimicrobial effects further support its therapeutic potential. Pinosylvin's anticancer mechanisms involve inhibiting cancer proliferation and metastasis while inducing apoptosis. These effects may be attributed to the compound's ability to modulate critical enzymes and pathways, underscoring its potential as a natural anticancer agent. However, further research, including clinical trials, is required to fully establish its efficacy and applicability in cancer treatment protocols.
Indexed as
Identifiers
39918573What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.